Finance

<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title">HotSpot heads for clinic with $65M series B round to develop allosteric modulators</h1><h2 class="title-bottom webtitle">With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO</h2><div class="byline">Paul Bonanos, Associate Editor</div><div class="date"></div></div></div></div>

HotSpot Therapeutics Inc.

Ribosomal protein S6 kinase 70kDa polypeptide 1 (S6K1) (RPS6KB1)

Protein kinase C (PKC) theta (PRKCQ)

HotSpot heads for clinic with $65M series B round to develop allosteric modulators

With strategics and one crossover firm on board, HotSpot Therapeutics is likely to raise a mezzanine round before exploring a listing.

With strategics, one crossover on board, HotSpot is likely to raise mezzanine round before exploring IPO

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>